Recent Updates
Recently added Catalysts

APG -2449

Phase 1

Platinum-resistant Recurrent Ovarian Cancer | Small molecule | Oncology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Feb 26, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment50
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STPHASE1 RECRUITING 50 — — Dec 17, 2024May 1, 2027Feb 26, 20251 China
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
APG -2449DRUGOrally once a day(QD), every 28 days as a cycle.
PLDDRUGInjected on the first day of each cycle, every 28 days as a cycle.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06687070studyFirstPostDate: changed